

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/827,666	04/06/2001	Timothy J. Neuberger	365279-001	6738
23565 7:	590 10/06/2006		EXAMINER	
KLAUBER & JACKSON			KWON, BRIAN YONG S	
411 HACKENSACK AVENUE HACKENSACK, NJ 07601			ART UNIT	PAPER NUMBER
	•		1614	
			DATE MAILED: 10/06/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/827,666	NEUBERGER ET AL.			
Office Action Summary	Examiner	Art Unit			
	Brian S. Kwon	1614			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION  16(a). In no event, however, may a reply be tin  11 apply and will expire SIX (6) MONTHS from  12 cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status		•			
1) Responsive to communication(s) filed on 10 Ju  2a) This action is FINAL.  2b) This  3) Since this application is in condition for allowan closed in accordance with the practice under E	action is non-final. ace except for formal matters, pro	•			
Disposition of Claims		·			
4) ⊠ Claim(s) 8-11,19-21,24,27,29-31,34-51 and 55-4a) Of the above claim(s) 29-31,37-45 and 59-65 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 8-11, 19-21, 24, 27, 34-36, 46-51, 55-	66 is/are withdrawn from conside	ration.			
Application Papers		•			
9) The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the o					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119	•				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:					
a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received.					
Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) ∐ Interview Summary Paper No(s)/Mail Da				
3) Information Disclosure Statement(s) (PTO/SB/08)	5) 🔲 Notice of Informal P				
Paper No(s)/Mail Date 6)					

Application/Control Number: 09/827,666

Art Unit: 1614

## **DETAILED ACTION**

1. Upon further consideration, the indicated allowability of claims 73-74 is withdrawn.

## Election/Restrictions

- Supplemental restriction to one of the following inventions is required under 35 U.S.C.
   121:
  - I. Claims 8-11, 19-21, 24, 27, 55-56 and 67-71, drawn to a method of increasing neural expression of one or more proteins on neural precursor cells in vitro, classified in class 435, subclass 353-354.
  - II. Claims 34-36 and 55-58, drawn to a method of promoting growth or differentiation of neural precursor cells in ex vivo, classified in class 435, subclass 368.
  - III. Claims 46-51 and 73-74, drawn to a method for treating injury to nervous system tissue in a mammal, classified in class 514, subclass 381.

Inventions I-III are directed to related processes. The related inventions are distinct if the (1) the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect; (2) the inventions do not overlap in scope, i.e., are mutually exclusive; and (3) the inventions as claimed are not obvious variants. See MPEP § 806.05(j). In the instant case, the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function or effect as described above. Furthermore, the invention III can be practiced with the materially different

Application/Control Number: 09/827,666

Art Unit: 1614

design, different mode of operation or function, for example by transplanting integrated elongated neuronal cells (USP 6365153), by administering CST neurotrophin to the legion (US 6167888), by administering liposome containing dichloromethylene diphosphonate (USP 5932563) or by attenuating nervous system damage after injury which comprises administering therapeutic amounts of PREG, PREG-S or esters of PREG or PREG-S together with an enhancer of secretory processes in non-neural cells such as bacterial lipopolysaccharide and a non-steroidal anti-inflammatory substance such as indomethacin (USP 5756482).

Furthermore, the inventions as claimed do not encompass overlapping subject matter and there is nothing of record to show them to be obvious variants.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

- 3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/827,666 Page 4

Art Unit: 1614

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Kwon whose telephone number is (571) 272-0581. The examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached on (571) 272-0718. The fax number for this Group is (571) 273-8300.

Any inquiry of a general nature of relating to the status of this application or proceeding. should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications may be obtained from Private PAIR only. For more information about PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a> Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Brian Kwon

Primary Patent Examiner
AU 1614

Bul